The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development
Open accessAbstract
SARS-COV-2 has roused the scientific community with a call to action to combat the growing pandemic. At the time of this writing, there are yet no novel antiviral agents or approved vaccines available to be deployed as a frontline defense. Understanding the pathobiology of COVID-19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. One method to accomplish this is the leveraging of computational methods to discover new candidate drugs and vaccines in silico. In the last decade, machine learning-based models, trained on specific biomolecules, have offered both inexpensive and rapid implementation methods for the discovery of effective viral therapies. Given a target biomolecule, these models are capable of predicting inhibitor candidates in a structural-based manner. If enough data are presented to a model, they can aid the search for a drug or vaccine candidate by identifying patterns within the data. In this review, we focus on the recent advances of COVID-19 drug and vaccine development using artificial intelligence, and the potential of intelligent training for the discovery of COVID-19 therapeutics. To facilitate the applications of deep learning for SARS-COV-2, we highlight multiple molecular targets of COVID-19, inhibition of which may increase patient survival. Moreover, we present CoronaDB-AI, a dataset of compounds, peptides, and epitopes discovered either in silico or in vitro that can be potentially used for training models. The information and datasets provided in this review can be used to train deep learning-based models and accelerate the discovery of effective viral therapies y.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding
Devlin, J., Chang, M.-W., Lee, K., & Toutanova, K. (2019) · Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers) · doi:10.18653/v1/n19-1423 · Cited by 54,325
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676 · cited 1×
“The host receptor ACE2 is another possible target, but the presence of ACE2 in non-lung tissues such as heart, kidney, and intestine (Hamming et al., 2004) could complicate its inhibition.”
BackgroundA SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning
Alipanahi, B., Delong, A., Weirauch, M. T., & Frey, B. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3300 · Cited by 2,873
Duan, Y., Edwards, J. S., & Dwivedi, Y. K. (2019) · International Journal of Information Management · doi:10.1016/j.ijinfomgt.2019.01.021 · Cited by 2,628
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123 · cited 2×
“There have been several other applications of multi-task deep learning models for identifying existing drugs that can target the main viral proteins, especially the main protease (3CL pro ) and spike protein (Hu et al., 2020; Kadioglu et al., 2020; Kim J. et al., 2020; Redka et al., 2020).”
BackgroundCytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912 · cited 1×
“Overactive release of pro-inflammatory cytokines, i.e., cytokine storm (CS), has been found in COVID-19 patients and can lead to severe complications like acute respiratory distress syndrome (ARDS) (Moore and June, 2020).”
Background
Cited by
Plant-derived natural products for drug discovery: current approaches and prospects
Nasim, N., Sandeep, I. S., & Mohanty, S. (2022) · The Nucleus · doi:10.1007/s13237-022-00405-3 · Cited by 598
Machine learning-based approach: global trends, research directions, and regulatory standpoints
Pugliese, R., Regondi, S., & Marini, R. (2021) · Data Science and Management · doi:10.1016/j.dsm.2021.12.002 · Cited by 373
Advances in De Novo Drug Design: From Conventional to Machine Learning Methods
Mouchlis, V. D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A. G., Aidinis, V., Lynch, I., Greco, D., & Melagraki, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041676 · Cited by 353
Application of Artificial Intelligence in Medicine: An Overview
Liu, P.-R., Lu, L., Zhang, J.-Y., Huo, T.-T., Liu, S.-X., & Ye, Z.-W. (2021) · Current Medical Science · doi:10.1007/s11596-021-2474-3 · Cited by 258
Dankwa-Mullan, I., Scheufele, E. L., Matheny, M. E., Quintana, Y., Chapman, W. W., Jackson, G., & South, B. R. (2021) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2021.0065 · Cited by 108
The machine learning life cycle and the cloud: implications for drug discovery
Spjuth, O., Frid, J., & Hellander, A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1932812 · Cited by 67
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Cao, L., & Liu, Q. (2022) · doi:10.1101/2022.08.22.22279022 · Cited by 49
Domain Shifts in Machine Learning Based Covid-19 Diagnosis From Blood Tests
Roland, T., Böck, C., Tschoellitsch, T., Maletzky, A., Hochreiter, S., Meier, J., & Klambauer, G. (2022) · Journal of Medical Systems · doi:10.1007/s10916-022-01807-1 · Cited by 42
Metadata
- Authors
- Keshavarzi Arshadi, A., Webb, J., Salem, M., Cruz, E., Calad-Thomson, S., Ghadirian, N., Collins, J., Diez-Cecilia, E., Kelly, B., Goodarzi, H., & Yuan, J. S.
- Venue
- Frontiers in Artificial Intelligence
- Publisher
- Frontiers Media SA
- Published
- 2020-08-18
- Volume
- 3
- Pages
- 65-65
- ISSN
- 2624-8212 (ISSN-L)
- OpenAlex
- W3077459578
- Cited by
- 244
- References
- 28
- FWCI
- 20.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.